Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase). AIM: To evaluate patient-reported outcomes (PROs) in this population. METHODS: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. RESULTS: In the high TMB population, PRO questionnaire completion rates were ∼90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. CONCLUSION: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. CLINICAL TRIAL REGISTRATION: NCT02477826.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 9×
“Nivolumab monotherapy demonstrated an overall survival (OS) benefit that translated into improved PROs versus standard of care in phase III studies in previously treated, advanced squamous [7,8] and non-squamous [9,10] NSCLC.”
BackgroundInfluentialSelf-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“Nivolumab monotherapy demonstrated an overall survival (OS) benefit that translated into improved PROs versus standard of care in phase III studies in previously treated, advanced squamous [7,8] and non-squamous [9,10] NSCLC.”
BackgroundSelf-citationEQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613 · cited 2×
“The EQ-5D comprises a VAS of general health status ranging from 0 (worst imaginable) to 100 (best imaginable) and a descriptive system based on five dimensions of health status: mobility, self-care, usual activities, pain/discomfort and anxiety/depression [16].”
BackgroundMethodNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 14×
“The PROs evaluated as prespecified exploratory end-points included deterioration rate by week 12 in the LCSS ASBI; mean scores and mean changes from baseline in the LCSS ASBI and 3-IGI, their individual components and the EQ-5D VAS and UI; longitudinal mixed-effect model repeated measures (MMRMs) analysis of scores on…”
BackgroundResultInfluentialSelf-citationU.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0830 · Cited by 2,593
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653
Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., Appawu, M., Iasonos, A., Atkinson, T., Goldfarb, S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp386 · Cited by 624 · cited 1×
“Although treatment-related adverse events were measured and reported in the primary manuscript [11], symptomatic side-effects of treatment may be underreported by physicians [31,32].”
BackgroundBrahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Self-citationHollen, P. J., Gralla, R. J., Kris, M. G., & Potanovich, L. M. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80262-x · Cited by 303
Hollen, P. J., Gralla, R. J., Kris, M. G., Cox, C., Belani, C. P., Grunberg, S. M., Crawford, J., & Neidhart, J. A. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2087::aid-cncr2820730813>3.0.co;2-x · Cited by 239
Health-related quality of life and cancer clinical trials
Osoba, D. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010395342 · Cited by 231
on behalf of the Medical Research Council (MRC) Lung Cancer Working Party, Hopwood, P., & Stephens, R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.124 · Cited by 192 · cited 1×
“Advanced nonesmall-cell lung cancer (NSCLC) is associated with substantial symptom burden, which negatively affects patients’ health-related quality of life (HRQoL) [1,2].”
BackgroundSurvivorship in Non–Small Cell Lung Cancer: Challenges Faced and Steps Forward
Vijayvergia, N., Shah, P. C., & Denlinger, C. S. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0140 · Cited by 122 · cited 12×
“These results, together with the demonstrated efficacy and manageable safety profile previously reported for nivolumab plus ipilimumab in this study [11], provide further evidence of the benefits of first-line nivolumab plus ipilimumab in patients with advanced NSCLC and high TMB.”
BackgroundInfluentialNormative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)
Hollen, P. J., Gralla, R. J., Kris, M. G., Eberly, S. W., & Cox, C. (1999) · Supportive Care in Cancer · doi:10.1007/s005200050244 · Cited by 119 · cited 2×
“the smallest change considered clinically meaningful, was defined as 10 points for the individual items of the LCSS and LCSS ASBI [17].”
BackgroundReck, M., Taylor, F. C., Penrod, J. R., DeRosa, M., Morrissey, L., Dastani, H. B., Orsini, L. S., & Gralla, R. J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.029 · Cited by 116 · cited 15×
“Nivolumab monotherapy demonstrated an overall survival (OS) benefit that translated into improved PROs versus standard of care in phase III studies in previously treated, advanced squamous [7,8] and non-squamous [9,10] NSCLC.”
BackgroundMethodResultInfluentialSelf-citationQuality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)
Hollen, P. J., Gralla, R. J., Kris, M. G., & Cox, C. (1994) · Supportive Care in Cancer · doi:10.1007/bf00365725 · Cited by 90
Bordoni, R. E., Ciardiello, F., von Pawel, J., Cortinovis, D. L., Karagiannis, T., Ballinger, M. D., Sandler, A. B., Yu, W., He, P., Matheny, C., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.05.011 · Cited by 76 · cited 1×
“Our findings are consistent with previous reports showing an improved impact on symptom burden and HRQoL for immunotherapy versus chemotherapy across first-line [22] and previously treated [8,10,23,24] NSCLC.”
ResultBarlesi, F., Garon, E. B., Kim, D.-W., Felip, E., Han, J.-Y., Kim, J.-H., Ahn, M.-J., Fidler, M. J., Gubens, M. A., de Castro, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.016 · Cited by 72
Reck, M., Brahmer, J. R., Bennett, B., Taylor, F. C., Penrod, J. R., DeRosa, M., Dastani, H. B., Spigel, D. R., & Gralla, R. J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.005 · Cited by 71
Self-citationTrustworthiness of Patient-Reported Outcomes in Unblinded Cancer Clinical Trials
Atkinson, T. M., Wagner, J.-S., & Basch, E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3328 · Cited by 65
Gralla, R. J., Hollen, P. J., Msaouel, P., Davis, B. V., & Petersen, J. A. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000244 · Cited by 60 · cited 1×
“Advanced nonesmall-cell lung cancer (NSCLC) is associated with substantial symptom burden, which negatively affects patients’ health-related quality of life (HRQoL) [1,2].”
BackgroundYang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 57
Liang, H., Lin, G., Wang, W., Huang, J., Yang, Y., Lan, Y., Wang, R., Cui, F., Hao, Z., Deng, H., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.14 · Cited by 45
Bevins, N., Sun, S., Gaieb, Z., Thorson, J., & Murray, S. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000613 · Cited by 38
Huang, D., Zhang, F., Tao, H., Zhang, S., Ma, J., Wang, J., Liu, Z., Cui, P., Chen, S., Huang, Z., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00703-3 · Cited by 35
Patient-reported outcomes with nivolumab in advanced solid cancers
Tykodi, S. S., Schadendorf, D., Cella, D. F., Reck, M., Harrington, K. J., Wagner, S., & Shaw, J. W. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.001 · Cited by 26 · cited 1×
“Immunotherapies have also shown a similar trend in other tumour types [25,26].”
ResultSelf-citationAbdel-Rahman, O. M., Oweira, H., & Giryes, A. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1528146 · Cited by 26 · cited 1×
“Immunotherapies have also shown a similar trend in other tumour types [25,26].”
ResultCavanna, L., Citterio, C., & Orlandi, E. (2020) · Patient Related Outcome Measures · doi:10.2147/prom.s179185 · Cited by 10
Symanowski, J. T., Gralla, R. J., & Hollen, P. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.7588 · Cited by 4 · cited 1×
“We constructed a LCSS three-item global index (3-IGI) as the sum of the scores for the three global items (range 0e300), with higher scores representing better HRQoL; this exploratory end-point has been previously described [8,10,18].”
Method
Cited by
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Wang, Y., Zhang, H., Liu, C., Wang, Z., Wu, W., Zhang, N., Zhang, L., Hu, J., Luo, P., Zhang, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01325-0 · Cited by 257
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 255
Metadata
- Authors
- Reck, M., Schenker, M., Lee, K. H., Provencio, M., Nishio, M., Lesniewski-Kmak, K., Sangha, R., Ahmed, S., Raimbourg, J., Feeney, K., Corre, R., Franke, F. A., Richardet, E., Penrod, J. R., Yuan, Y., Nathan, F. E., Bhagavatheeswaran, P., DeRosa, M., Taylor, F., Lawrance, R., & Brahmer, J.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 116
- Pages
- 137-147
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2949515538
- Cited by
- 215
- References
- 31
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.